Incyte ( Incyte)

Primary tabs

Incyte's picture

Management

Contact Address

About Incyte

Incyte’s goal is to become one of the leading global biopharmaceutical companies. Incyte is a company founded on the premise that investment in good science and the rigorous pursuit of R&D excellence can translate into new medicines that can positively affect patients’ lives. We have an experienced team with a track record of success, and our goal is to create first-in-class and best in class therapeutics. We pursue this by combining critical target selection with our world-class medicinal chemistry expertise.

Incyte press release, blog etc

Sun, 03/13/2022 - 21:38 Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura) for the Treatment of Vitiligo
Fri, 11/12/2021 - 21:34 Data from Incytes Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
Sun, 10/31/2021 - 21:36 Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
Fri, 10/15/2021 - 06:07 Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021
Wed, 09/29/2021 - 21:19 Incyte Provides Update on Parsaclisib and MCLA-145
Sun, 09/26/2021 - 22:34 Incyte Names New Member to Its Board of Directors
Mon, 09/13/2021 - 03:55 Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Tue, 08/03/2021 - 17:31 Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
Sun, 07/25/2021 - 16:44 Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Sun, 07/25/2021 - 16:29 Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Tue, 06/29/2021 - 20:31 Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
Thu, 06/24/2021 - 16:58 Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Sun, 06/13/2021 - 15:46 Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
Fri, 06/11/2021 - 17:37 Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
Tue, 06/08/2021 - 18:17 Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease (GVHD)
Tue, 04/20/2021 - 16:10 Multiple Abstracts from Incytes Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience
Wed, 03/31/2021 - 17:49 Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
Wed, 11/27/2019 - 08:02 Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
more

InfoBox

HomePagewww.incyte.com
Twittertwitter.com/Incyte
LinkedInwww.linkedin.com/company/6761
Wikipediaen.wikipedia.org/wiki/Incyte